
AstraZeneca’s hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) roxadustat has made a strong showing in the treatment of deficient haemoglobin (Hb) …

Astellas has revealed new Phase 3 data for roxadustat in the treatment of chronic kidney disease (CKD) in patients with …

